Current Report Filing (8-k)
29 Março 2019 - 10:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
March
29, 2019
Vycor
Medical, Inc.
(Exact
name of registrant)
Delaware
|
|
001-34932
|
|
20-3369218
|
(State
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification
Number)
|
951
Broken Sound Parkway, Suite 320
Boca
Raton, FL 33487
(Address
of principal executive offices and zip code)
561-558-2020
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
TABLE
OF CONTENTS
Item
2.02. Results of Operations and Financial Conditions
The
information in this report and the exhibit attached hereto are being furnished pursuant to Item 2.02 of Form 8-K and shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated
by reference in any filing with the Securities and Exchange Commission under the Securities Act of 1934 or the Securities Act
of 1933, except as shall be expressly set forth by specific reference to such filing.
On
March 29, 2019, we issued a press release regarding our financial results for the year ended December 31, 2018. A copy of the
press release is furnished as Exhibit 99.1 to this Form 8-K.
Non-GAAP
Measures
We
make reference to non-GAAP financial information in this press release together with a reconciliation of these non-GAAP financial
measures to the comparable GAAP financial measures. Specifically, we have provided non-GAAP Cash Operating Expenses and non-GAAP
Cash Operating Loss measures that exclude Depreciation, Amortization and non-cash Stock Compensation.
We
believe that these non-GAAP financial measures provide investors with insight into what is used by management to conduct a more
meaningful and consistent comparison of our ongoing operating results and trends, compared with historical results. This presentation
is also consistent with the measures management uses to measure the performance of ongoing operating results against prior periods
and against our internally developed targets. There are limitations in using these non-GAAP financial measures because they are
not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP
financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential
investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements
prepared in accordance with GAAP and the reconciliation of non-GAAP financial measures in this press release.
Item
9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
VYCOR
MEDICAL, INC.
|
|
|
|
|
By:
|
/s/
Peter Zachariou
|
|
Name:
|
Peter
Zachariou
|
|
Title:
|
Chief
Executive Officer
|
Dated:
March 29, 2019
Vycor Medical (QB) (USOTC:VYCO)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025
Vycor Medical (QB) (USOTC:VYCO)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025
Notícias em tempo-real sobre Vycor Medical Inc (QB) da OTCMarkets bolsa de valores: 0 artigos recentes
Mais Notícias de Vycor Medical Inc